Literature DB >> 17125448

The endocannabinoid system.

Steven T Boyd1.   

Abstract

The endocannabinoid system is a complex physiologic system. One of the most important discoveries related to the endocannabinoid system is that cannabinoid-1 receptors are present throughout the body and that they are linked to obesity and cardiometabolic risk. Adipose tissue was historically thought to be an inert, passive storage vehicle. However, recent findings prove that adipose tissue is a complex endocrine organ that releases adipokines, which influence cardiometabolic risk factors. Elevated endocannabinoid system activity is associated with obesity and coupled with excessive food intake and fat accumulation. Strong evidence suggests that the endocannabinoid system affects the surrogate cardiometabolic end points that greatly influence morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17125448     DOI: 10.1592/phco.26.12part2.218S

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  9 in total

1.  In silico investigation of interactions between human cannabinoid receptor-1 and its antagonists.

Authors:  Guanglin Kuang; Guoping Hu; Xianqiang Sun; Weihua Li; Guixia Liu; Yun Tang
Journal:  J Mol Model       Date:  2012-03-09       Impact factor: 1.810

Review 2.  Hemopressin and other bioactive peptides from cytosolic proteins: are these non-classical neuropeptides?

Authors:  Julia S Gelman; Lloyd D Fricker
Journal:  AAPS J       Date:  2010-04-10       Impact factor: 4.009

3.  Novel endogenous peptide agonists of cannabinoid receptors.

Authors:  Ivone Gomes; Julia S Grushko; Urszula Golebiewska; Sascha Hoogendoorn; Achla Gupta; Andrea S Heimann; Emer S Ferro; Suzanne Scarlata; Lloyd D Fricker; Lakshmi A Devi
Journal:  FASEB J       Date:  2009-04-20       Impact factor: 5.191

4.  Hemopressin is an inverse agonist of CB1 cannabinoid receptors.

Authors:  Andrea S Heimann; Ivone Gomes; Camila S Dale; Rosana L Pagano; Achla Gupta; Laura L de Souza; Augusto D Luchessi; Leandro M Castro; Renata Giorgi; Vanessa Rioli; Emer S Ferro; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-12       Impact factor: 11.205

Review 5.  Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse.

Authors:  Ivone Gomes; Wakako Fujita; Moraje V Chandrakala; Lakshmi A Devi
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

6.  Progesterone-dependent regulation of endometrial cannabinoid receptor type 1 (CB1-R) expression is disrupted in women with endometriosis and in isolated stromal cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).

Authors:  David Resuehr; Dana R Glore; Hugh S Taylor; Kaylon L Bruner-Tran; Kevin G Osteen
Journal:  Fertil Steril       Date:  2012-07-11       Impact factor: 7.329

7.  Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons.

Authors:  Qing Liu; Manjunatha Bhat; Wayne D Bowen; Jianguo Cheng
Journal:  J Pharmacol Exp Ther       Date:  2009-09-14       Impact factor: 4.030

8.  Tricyclic Pyrazoles. Part 5. Novel 1,4-Dihydroindeno[1,2-c]pyrazole CB2 Ligands Using Molecular Hybridization Based on Scaffold Hopping.

Authors:  Gabriele Murineddu; Battistina Asproni; Stefania Ruiu; Francesco Deligia; Matteo Falzoi; Amedeo Pau; Brian F Thomas; Yanan Zhang; Gérard A Pinna; Luca Pani; Paolo Lazzari
Journal:  Open Med Chem J       Date:  2012-05-17

Review 9.  New insights on atherosclerosis: A cross-talk between endocannabinoid systems with gut microbiota.

Authors:  Jalal Moludi; Mohammad Alizadeh; Ned Lotfi Yagin; Yahiya Pasdar; Seyed Mostafa Nachvak; Hadi Abdollahzad; Ali Sadeghpour Tabaei
Journal:  J Cardiovasc Thorac Res       Date:  2018-09-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.